Business Context and Reporting Period
Company: IRADIMED Corporation (IRMD)
Filing Type: Form 10-K (Annual Report)
Reporting Period: Fiscal Year Ended December 31, 2024
Business Overview: IRADIMED develops, manufactures, and markets MRI-compatible medical devices, primarily the MRidium IV infusion pump system and the 3880 patient vital signs monitoring system. The company operates as a single reportable segment, selling directly in the U.S. and through distributors internationally.
Key Financial Metrics
| Metric | 2024 | 2023 |
|---|---|---|
| Total Revenue | $73.2 million | $65.6 million |
| Gross Profit | $56.3 million | $50.2 million |
| Gross Margin | 76.9% | 76.5% |
| Operating Income | $22.0 million | $20.0 million |
| Operating Margin | 30.0% | 30.6% |
| Net Income | $19.2 million | $17.2 million |
| Diluted EPS | $1.50 | $1.35 |
| Cash from Operations | $25.6 million | $13.5 million |
| Cash & Investments (Year End) | $52.2 million | $49.8 million |
| Working Capital | $66.2 million | $59.7 million |
Material Changes vs. Prior Period
- Revenue Growth: Total revenue increased 12% ($7.6 million) driven by a 15.4% increase in U.S. sales ($60.6 million) and a 13% increase in device sales. International revenue declined slightly by 3.1%.
- Product Mix: IV Infusion Pump revenue grew significantly to $26.6 million (up from $19.6 million), while Vital Signs Monitor revenue decreased slightly to $24.4 million.
- Expense Trends: Sales and marketing expenses rose 28.6% to $15.6 million due to higher commissions and travel costs aligned with revenue growth. General and administrative expenses increased 5.4% to $15.9 million. R&D expenses remained flat at $2.8 million.
- Profitability: Gross margin improved to 76.9% due to favorable overhead variances, higher average selling prices, and reduced raw material costs.
- Liquidity: Cash provided by operating activities nearly doubled to $25.6 million, supported by higher net income and improved working capital management (lower inventory and accounts receivable).
Guidance, Outlook, and Risks
- Outlook: Management expects continued growth driven by market education on the safety risks of non-MRI compatible workarounds and expanded deployment in critical care units (ICU/ER) beyond radiology departments.
- Capital Allocation: The Board increased the quarterly cash dividend to $0.17 per share in February 2025. The company continues construction on a new corporate and manufacturing facility in Orange County, Florida, expected to be occupied in mid-2025.
- Key Risks:
- Product Concentration: Heavy reliance on the MRidium IV pump and 3880 Monitor; disruption to these products would materially impact the business.
- Supply Chain: Dependence on single-source suppliers for critical components, though the company recently secured a license to manufacture its own non-magnetic ultrasonic motors.
- Regulatory: Subject to FDA oversight; failure to maintain 510(k) clearances or comply with quality standards could halt sales.
- Key Person: Significant dependence on founder and CEO Roger Susi for product development and leadership.
Investor Verification Checklist
- Supply Chain Transition: Verify the timeline and success of the transition to in-house manufacturing of the non-magnetic ultrasonic motor to mitigate single-source risk.
- Facility Expansion: Monitor the completion and operational readiness of the new Orange County facility scheduled for mid-2025.
- International Sales: Investigate the reasons for the decline in international revenue (3.1% drop) despite overall growth.
- Regulatory Status: Confirm the status of the ongoing IRS examination for the 2021 tax year and any potential adjustments.
- Dividend Sustainability: Assess the impact of the increased dividend ($0.17/share) and capital expenditures on future cash flow flexibility.